Critically, the combination of BMS-911543, at a clinically achievable concentration, with TKIs displayed minimal toxic effects in CD34+ NBM cells compared to CD34+ CML cells (4-8% vs. 32-36%, P<0.01, Fig. 2B). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.